Peter Voorhees, MD

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.

Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.

Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.

Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.

Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.

Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.

The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.

Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.

Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.